Abstract
The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Current HIV Research
Title: Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count
Volume: 6 Issue: 1
Author(s): Claudio M. Mastroianni, Miriam Lichtner, Raffaella Rossi, Maria C. Rizza, Fabio Mengoni, Ilaria Sauzullo, Anna P. Massetti, Giuseppe Luzi, Anne Hosmalin and Vincenzo Vullo
Affiliation:
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Abstract: The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Export Options
About this article
Cite this article as:
Mastroianni M. Claudio, Lichtner Miriam, Rossi Raffaella, Rizza C. Maria, Mengoni Fabio, Sauzullo Ilaria, Massetti P. Anna, Luzi Giuseppe, Hosmalin Anne and Vullo Vincenzo, Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count, Current HIV Research 2008; 6 (1) . https://dx.doi.org/10.2174/157016208783571937
DOI https://dx.doi.org/10.2174/157016208783571937 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV vaccine development
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Contribution of Aspartic Proteases in Candida Virulence. Protease Inhibitors against Candida Infections
Current Protein & Peptide Science New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Discovery of Novel Tetramethylpyrazine Containing Chalcone Derivatives as Anti-Inflammatory Agents
Medicinal Chemistry Neuropeptide - Adipose Tissue Communication and Intestinal Pathophysiology
Current Pharmaceutical Design Multi-Target Drug Design Approaches for Multifactorial Diseases: From Neurodegenerative to Cardiovascular Applications
Current Medicinal Chemistry Biomolecules as Host Defense Weapons Against Microbial Pathogens
Recent Patents on DNA & Gene Sequences Current Pathogenesis of Alzheimer’s Disease and Plants Derived Neuroprotective Phytoconstituents: A Comprehensive Review
Current Psychopharmacology Differential Developmental Origin of Arteries: Impact on Angiogenesis and Arteriogenesis
Medicinal Chemistry Reviews - Online (Discontinued) Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Targeted Taxane Delivery Systems: Recent Advances
Drug Delivery Letters Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Immunoproteasome: An Emerging Therapeutic Target
Current Topics in Medicinal Chemistry Biomarkers Predicting a Need for Intensive Treatment in Patients with Early Arthritis
Current Pharmaceutical Design Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design The Role of Downstream Signaling Pathways of the Epidermal Growth Factor Receptor for Artesunates Activity in Cancer Cells
Current Cancer Drug Targets Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Current Signal Transduction Therapy Th17 Cells: The Role in Immunity
Current Immunology Reviews (Discontinued) Hepatobiliary Diseases and Insulin Resistance
Current Medicinal Chemistry